IIOT-OXYS, Inc. Enters into NDA with a Strategic New England-Based Medical Component Manufacturer
IIOT-OXYS, Inc. (OTC PINK:ITOX) has signed a Non-Disclosure Agreement (NDA) with a strategic medical component manufacturer in New England. CEO Cliff Emmons highlighted that this agreement marks the start of collaboration focused on enhancing manufacturing quality and productivity through edge computing and machine learning. This partnership expands IIOT-OXYS's engagement in discrete manufacturing, vital for medical devices. The company has now entered five such agreements this year, aiming to capitalize on the $76.7 billion IIoT market, projected to reach $106.1 billion by 2026.
- Execution of an NDA indicates a strategic partnership, potentially enhancing product quality and productivity.
- This is the fifth NDA signed in 2021, reflecting strong growth in IIOT-OXYS's engagement with the medical device sector.
- Partnerships in discrete manufacturing provide diversification and align with market demand in the IIoT sector.
- The company faces risks such as loss of major customers and difficulties in securing new contracts, as indicated in forward-looking statements.
CAMBRIDGE, MA / ACCESSWIRE / October 22, 2021 / IIOT-OXYS, Inc. (OTC PINK:ITOX) announced the execution of a Non-Disclosure Agreement (NDA) with a strategic New England-based medical component manufacturer.
Cliff Emmons, CEO of IIOT-OXYS, Inc., stated, "This customer manufactures world-class prototype and production metal components for Medical Device OEMs. They are known for their innovation and collaboration with their customers. Their expertise in precision metal stamped components includes design and fabrication of tooling and process development. The signing of an NDA is the first step in our collaboration with the customer. We are very pleased to be working with this strategic and innovative company that can leverage our technology to ensure the products and services they provide to their customers meet their manufacturing quality and productivity goals. We look forward to partnering with their technology-savvy leadership to see where our edge computing and machine learning algorithms will add the most value to their manufacturing equipment and processes and their medical device customers' components."
"This new potential customer continues to expand a strategic move for IIOT-OXYS, Inc.", explained Mr. Emmons. "We are expanding into ‘discrete manufacturing' processes applicable to medical devices, building on our successes with ‘continuous manufacturing' processes characteristic to biotech and pharmaceutical manufacturing. Precision metal stamping is a key manufacturing process for medical and surgical device components. This is the third (metal stamping, metal machining, and hot-melt plastic extrusion) of several strategic partners we are vetting in key manufacturing processes for medical devices, including plastic injection molding, and automated assembly."
"This is the fifth such agreement this year, which continues an expansion of our current biotech, pharmaceutical, and medical device intelligent manufacturing segments. Our strong partnerships, successful pilots and use cases, and extensive network and prospects, position us to win in the WW IIoT market, estimated at
1Industrial IoT Market Report, July 2021, MarketandMarkets Research Private Ltd.
Industrial IoT Market Size, Share and Trends Forecast to 2026 | MarketsandMarkets™
Forward-Looking Statements
This news release contains forward-looking statements that reflect Management's current views about future events and financial performance. Forward-looking statements often contain words such as ''expects,'' ''anticipates,'' ''intends,'' or ''believes.'' Our forward-looking statements are subject to a number of risks and uncertainties that may cause actual results and events to differ materially from those projected in the forward-looking statements. Risks and uncertainties that could adversely affect us include, without limitation, the loss of major customers, our failure to obtain new contracts, our inability to patent products or processes, our infringement of patents held by others, our inability to finance our business and the other risks and uncertainties that are discussed in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this news release are made only as of the date of this news release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.
About Us
IIOT-OXYS, Inc. is a technology company at the intersection of IIoT, AI & Machine Learning, Edge Computing and Manufacturing Operations. We provide actionable mission-critical insights for the Medical/Pharmaceutical, Manufacturing, Agriculture, Defense, and Structural Health, and other industries. IIOT-OXYS, Inc. edge computing open-source hardware and proprietary ML algorithms employ our Minimally Invasive Load Monitoring (MILM) technology to simply gather data and gain insights to monitor, scope, move from preventive to predictive maintenance, and even optimize development and manufacturing processes. For additional information visit www.oxyscorp.com.
CONTACT:
Clifford L. Emmons
CEO
IIOT-OXYS, Inc.
contact@oxyscorp.com
www.oxyscorp.com
SOURCE: IIOT-OXYS, Inc.
View source version on accesswire.com:
https://www.accesswire.com/669081/IIOT-OXYS-Inc-Enters-into-NDA-with-a-Strategic-New-England-Based-Medical-Component-Manufacturer
FAQ
What is the latest announcement from IIOT-OXYS (ITOX)?
How does the NDA with the medical manufacturer impact IIOT-OXYS (ITOX)?
How many strategic agreements has IIOT-OXYS (ITOX) signed this year?
What is the projected growth of the Industrial IoT market relating to IIOT-OXYS (ITOX)?
